Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer

11 juin 2026 mis à jour par: GlaxoSmithKline

Phase 4, Open Label, Single-arm, Interventional, Multicenter Study to Evaluate the Safety of Dostarlimab in Adult Patients in India With Primary Advanced or Recurrent Endometrial Cancer

This study will evaluate the safety of dostarlimab in combination with carboplatin and paclitaxel followed by monotherapy when administered as a first-line treatment in advanced or recurrent endometrial cancer (EC).

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Type d'étude

Interventionnel

Inscription (Estimé)

100

Phase

  • Phase 4

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Participant with greater than or equals to (>=) 18 years of age, at the time of signing the informed consent.
  • Participant has histologically or cytologically proven EC with recurrent or advanced disease.
  • Participant must have primary Stage III or Stage IV disease or first recurrent EC with a low potential for cure by radiation therapy or surgery alone or in combination based on investigator's assessment.
  • Eligible for dostarlimab treatment according to the approved prescribing information and the investigator's clinical judgement.
  • Woman of childbearing potential (WOCBP) agrees to use contraceptive from screening through at least 180 days after the last dose.
  • Negative urine pregnancy test at most 24 hours prior to the first dose of study intervention.
  • Capable of giving signed informed consent.
  • Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria:

  • Participant has had greater than (>) 1 recurrence of endometrial cancer.
  • Participant has a concomitant malignancy, or participant has a prior non endometrial invasive malignancy who has been disease-free for less than (<) 3 years or who received any active treatment in the last 3 years for that malignancy.
  • Participant has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both.
  • Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active infection requiring systemic therapy.
  • Participant has not recovered adequately from AEs or complications from any major surgery prior to starting therapy.
  • Participant has not recovered (i.e., to Grade less than or equal to [<=] 1 or to Baseline) from cytotoxic therapy induced AEs or has received transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including Granulocyte colony-stimulating factor [G-CSF], Granulocyte macrophage colony-stimulating factor [GM-CSF], or recombinant erythropoietin) within 21 days prior to the first dose of study drug.
  • Either the history of hypersensitivity to excipients of the study intervention or to drugs with a similar chemical structure or class of the study intervention.
  • Participant has known active hepatitis B (e.g., hepatitis B surface antigen reactive) or hepatitis C (e.g., hepatitis C virus ribonucleic acid [qualitative] is detected).
  • Participant has received neo-adjuvant/adjuvant systemic anticancer therapy for primary Stage III or IV disease and:

    • has not had a recurrence or Progressive disease (PD) prior to first dose on the study, or
    • has had a recurrence or PD within 6 months of completing systemic anticancer therapy treatment prior to first dose on the study.
  • Participant has received prior therapy with an anti- Programmed death protein 1 (anti-PD-1), anti- Programmed death ligand 1 (anti-PD-L1), or Programmed death ligand 2 (anti PD L2) agent.
  • Participant has received prior anticancer therapy (chemotherapy, targeted therapies, radiotherapy, or immunotherapy) within 21 days or <5 times the half life of the most recent therapy prior to study Day 1, whichever is shorter.
  • Systemic glucocorticoids for any purpose other than to manage symptoms of suspected irAEs. If medically deemed necessary (e.g., acute asthma or chronic obstructive pulmonary disease exacerbation, prophylaxis for intravenous (IV) contrast if indicated), Investigators are allowed to use their judgment to treat participants with systemic steroids. In such cases, systemic steroids should be stopped at least 24 hours prior to the next dose of study treatment.
  • Participant has received, or is scheduled to receive, a live vaccine within 30 days before first dose of study intervention, during study treatment, and for up to 180 days after receiving the last dose of study intervention.
  • Participant has a diagnosis of immunodeficiency and is receiving systemic steroid therapy (>10 milligrams [mg] daily prednisone or equivalent) within 7 days prior to the first dose of the study treatment or is receiving any other form of immunosuppressive medication.
  • Participant is currently receiving study intervention, or is enrolled or has participated in any other clinical study involving an investigational intervention and received investigational treatment or used an investigational device within 4 weeks of the first dose of dostarlimab.
  • Participant is pregnant or breastfeeding or is expecting to conceive children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of study intervention.
  • Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Participants receiving Dostarlimab with Carboplatin + Paclitaxel followed by Dostarlimab Monotherapy
Participants will receive dose level 1 of dostarlimab in combination with carboplatin and paclitaxel followed by dose level 2 of dostarlimab monotherapy. Dose level 1 is the lowest dose level.
Le dostarlimab sera administré.
Le carboplatine sera administré.
Paclitaxel sera administré.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Délai
Number of participants with Grade 3 or greater treatment-emergent adverse events (TEAEs) up to Week 49
Délai: Up to Week 49
Up to Week 49

Mesures de résultats secondaires

Mesure des résultats
Délai
Number of participants with Grade 3 or greater TEAEs up to Week 170
Délai: Up to Week 170
Up to Week 170
Number of participants with TEAEs up to Week 49
Délai: Up to Week 49
Up to Week 49
Number of participants with TEAEs up to Week 170
Délai: Up to Week 170
Up to Week 170
Number of participants with Immune-related adverse events (irAEs) up to Week 49
Délai: Up to Week 49
Up to Week 49
Number of participants with Immune-related adverse events (irAEs) up to Week 170
Délai: Up to Week 170
Up to Week 170
Number of Participants with Serious Adverse Events (SAEs), treatment related Adverse Events (AEs), treatment related SAEs, fatal AEs, non-fatal SAEs up to Week 49
Délai: Up to Week 49
Up to Week 49
Number of Participants with Serious Adverse Events (SAEs), treatment related Adverse Events (AEs), treatment related SAEs, fatal AEs, non-fatal SAEs up to Week 170
Délai: Up to Week 170
Up to Week 170
Number of Participants with AEs leading to discontinuation of treatment, AEs leading to study withdrawal and AEs leading to dose modification up to Week 49
Délai: Up to Week 49
Up to Week 49
Number of Participants with AEs leading to discontinuation of treatment, AEs leading to study withdrawal and AEs leading to dose modification up to Week 170
Délai: Up to Week 170
Up to Week 170
Change from Baseline in hematology parameters: neutrophils, lymphocytes, monocytes, eosinophils, basophils and platelet count (Giga cells per Liter) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in hematology parameters: neutrophils, lymphocytes, monocytes, eosinophils, basophils and platelet count (Giga cells per Liter) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in hematology parameter: Red Blood Cell (RBC) count (Trillion cells per Liter) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in hematology parameter: Red Blood Cell (RBC) count (Trillion cells per Liter) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in hematology parameter: Hemoglobin (Hb) (Grams per Liter) up to Week 49
Délai: Baseline (Day 1) and up to 49
Baseline (Day 1) and up to 49
Change from Baseline in hematology parameter: Hemoglobin (Hb) (Grams per Liter) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in hematology parameter: Reticulocytes (Percentage of reticulocytes) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in hematology parameter: Reticulocytes (Percentage of reticulocytes) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in hematology parameter: Mean Corpuscular Volume (MCV) (Femtoliters) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in hematology parameter: Mean Corpuscular Volume (MCV) (Femtoliters) to up to Week 170
Délai: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in hematology parameter: Mean Corpuscular Hemoglobin (MCH) (Picograms) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in hematology parameter: Mean Corpuscular Hemoglobin (MCH) (Picograms) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in clinical chemistry parameters: Blood urea nitrogen (BUN), glucose, calcium, sodium, and potassium levels (Millimoles per Liter) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in clinical chemistry parameters: Blood urea nitrogen (BUN), glucose, calcium, sodium, and potassium levels (Millimoles per Liter) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in clinical chemistry parameters: Total bilirubin, direct bilirubin and creatinine levels (Micromoles per Liter) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in clinical chemistry parameters: Total bilirubin, direct bilirubin and creatinine levels (Micromoles per Liter) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in clinical chemistry parameters: Total protein levels (Gram per liter) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in clinical chemistry parameters: Total protein levels (Gram per liter) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in clinical chemistry parameters: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels (International units per liter) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in clinical chemistry parameters: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels (International units per liter) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in Vital signs: systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Millimeters of mercury [mmHg]) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in Vital signs: systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Millimeters of mercury [mmHg]) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in Vital signs: pulse rate (Beats per minute) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in Vital signs: pulse rate (Beats per minute) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in Vital signs: body temperature (Degrees Celsius) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in Vital signs: body temperature (Degrees Celsius) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in Vital signs: respiratory rate (breaths per minute) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in Vital signs: respiratory rate (breaths per minute) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in electrocardiogram (ECG) values: Heart rate (Beats per minute) up to Week 49
Délai: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in electrocardiogram (ECG) values: Heart rate (Beats per minute) up to Week 170
Délai: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Directeur d'études: GSK Clinical Trials, GlaxoSmithKline

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

17 août 2026

Achèvement primaire (Estimé)

30 août 2030

Achèvement de l'étude (Estimé)

30 août 2030

Dates d'inscription aux études

Première soumission

11 juin 2026

Première soumission répondant aux critères de contrôle qualité

11 juin 2026

Première publication (Réel)

17 juin 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 juin 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

11 juin 2026

Dernière vérification

1 juin 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Délai de partage IPD

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Critères d'accès au partage IPD

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • CIF
  • RSE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Oui

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner